Endogastric Solutions Launches Esophyx2
Next-Generation Device Makes Revolutionary TIF2 Procedure Better, Faster, Easier
Redwood City, CA December 3, 2008 - EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced the launch of the EsophyX2 device. The next generation of its innovative EsophyX® device, EsophyX2 facilitates the creation of a robust, tight antireflux valve with the TIF2 (transoral incisionless fundoplication) advanced surgical procedure for the treatment of GERD (gastroesophageal reflux disease).
"EsophyX2 is the result of EGS’ experience with nearly 1,000 TIF procedures worldwide and our research and development efforts to advance the device to facilitate even better patient outcomes," commented Richard Romley, Endogastric Solutions’ Senior Vice President of Operations and R&D. "As with most surgical procedures, TIF has been an evolution. EsophyX2 was designed to facilitate a tight, robust valve with the TIF2 procedure which we believe will produce excellent patient outcomes. This next generation device offers several significant enhancements, including a redesigned tissue mold, a quick-loading multifastener cartridge, and simplified controls."
"Constructing a tight antireflux valve is critical to the success of the procedure," explained W. Scott Melvin, MD, Professor of Surgery at The Ohio State University Center for Minimally Invasive Surgery. "EsophyX2 handles more precisely and maneuvers more firmly into the corners of the valve, allowing me to mold and secure a tight valve. EsophyX2 allows me to offer my patients a surgical solution to their reflux without the risk of dysphagia, gas bloat and other side effects which can occur with more invasive laparoscopic procedures. Our early results with the next generation EsophyX2 device have been encouraging."
EsophyX2 is a breakthrough transoral incisionless surgical device introduced into the body through a natural body orifice, the mouth, not through an incision. The advantages of incisionless surgery over laparoscopic or open surgery include lower complication rate, reduced patient discomfort, no scars, resulting in higher patient satisfaction. The clinically-proven TIF procedure is based on many years of well-established surgical fundoplication concepts and techniques for the successful treatment of GERD. TIF works by reconstructing an antireflux barrier at the gastroesophageal junction, restoring natural anatomical geometry to effectively treat GERD.
More than 21 million people in the U.S. alone suffer from GERD, also known as chronic acid reflux, a progressive disease. Although moderate to severe acid reflux is typically treated with medications such as PPIs (proton pump inhibitors) and histamine receptor antagonists (H2 blockers), these medications can lose their effectiveness over time, requiring progressively higher dosing. In addition, known side effects of long-term use of PPIs include osteomalacia (inadequate absorption of calcium and other minerals into the bones). Recent case studies on the adverse effects of long-term PPI use indicate a significantly higher incidence of hip fractures, particularly among women.
Professor Guy-Bernard Cadière, MD, PhD, Chief of Gastrointestinal Surgery, Saint Pierre University Hospital, Brussels, Belgium, commented, "The new EsophyX2 device makes the TIF procedure easier, quicker and more reproducible. It’s improved ease of use has helped to reduce the overall procedure time and is enabling us to build better, much tighter valves, which will certainly result in improved patient outcomes."
Thierry Thaure, Chief Executive Officer of EndoGastric Solutions, said, "EsophyX2’s many significant enhancements illustrate our commitment to advancing the TIF procedure and the NOS field as a whole. EsophyX and our other NOS product, StomaphyX, for transoral tissue fastening, are the first of a rich pipeline of transoral incisionless intragastric surgery products under development at EndoGastric Solutions. They are helping to usher in the future of surgery " NOS, the next step beyond laparoscopy."
About EndoGastric Solutions
EndoGastric Solutions (EGS) is a privately held corporation located in Redmond, Washington, and Redwood City, California. EGS is a pioneer in developing incisionless transoral procedures for the treatment of upper gastrointestinal conditions, including gastroesophageal reflux disease (GERD) and other GI conditions. EsophyX® and StomaphyX® are cleared by the FDA, CE marked, and available for sale in the U.S. and other parts of the world.
For more information about EndoGastric Solutions, Inc., and EsophyX, please visit:
EndoGastric Solutions, Inc.
(650) 610-9250 ext. 236
EndoGastric Solutions, Inc.
EUROPEAN CUSTOMER CONTACT:
General Manager, EGS Europe
+33 6 7525 8382
Contact us via
email or phone or register for an appointment.
Read more about morbid
obesity surgery, bariatric surgery, or gastric bypass surgery, or LapBand®.